A Canadian study is underway and is currently seeking participants to determine the safety and efficacy of vitamin D supplementation in patients with colorectal cancer.
The organization conducting the study, InspireHealth, is an integrative cancer care center working to provide care for people living with cancer.
There is a large amount of evidence that suggests that vitamin D plays a role in colorectal cancer. In fact, colorectal cancer was the first form of cancer to be studied for a potential relationship to vitamin D.
InspireHealth is seeking participants that live in British Columbia, Canada and who have stage 4 colorectal cancer for a 28 month study.
The study design is a randomized non-blinded trial. Treatment group participants will be given a starting dose of 10,000 IU/day of vitamin D and control group participants will not be given vitamin D but may continue with their usual vitamin D supplementation.
Throughout the course of the study, participants will be asked to have laboratory tests done on a regular basis. The laboratory tests include serum vitamin D levels and will be done every month for treatment group participants, and every 8 months for control group participants. Treatment group participants will have their dose of supplemental vitamin D adjusted to reach and maintain a blood level range of between 80 and 100 ng/ml.
At the end of this trial, InspireHealth hopes to have strong evidence on whether or not vitamin D has therapeutic effects in those with advanced colorectal cancer.
If you fit their eligibility criteria and are interested in participating, please contact the study coordinator at vitDstudy@inspirehealth.ca, or by calling 604-734-7125.